<DOC>
	<DOCNO>NCT02143635</DOCNO>
	<brief_summary>To determine evaluate safe tolerate dose HDM201 adult patient select advanced tumor characterize wild-type TP53 .</brief_summary>
	<brief_title>Study Determine Evaluate Safe Tolerated Dose HDM201 Patients With Selected Advanced Tumors That Are TP53wt</brief_title>
	<detailed_description />
	<mesh_term>Li-Fraumeni Syndrome</mesh_term>
	<criteria>Patient TP53wt locally advance metastatic solid malignancy measurable nonmeasurable ( evaluable ) disease determine RECIST 1.1 criterion . Patients TP53wt hematological tumor ( AML , ALL , HRMDS ) fail prior therapy consider inappropriate candidate standard induction therapy . Other protocoldefined inclusion criterion may apply Prior treatment compound mode action Subjects significant uncontrolled cardiovascular disease History thromboembolic cerebrovascular event within last 6 month , include transient ischemic attack , cerebrovascular accident , deep vein thrombosis , pulmonary embolism Previous concomitant therapy precludes enrollment , define protocol Known Human Immunodeficiency Virus ( HIV ) infection and/or active Hepatitis B Hepatitis C infection Patients undergone major surgery within 2 week prior start study treatment fully recover previous surgery Women childbearing potential , unless use highly effective method contraception dose 2 week study drug discontinuation Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HDM201 , TP53wt , p53 , MDM2 , HDM2 , advance tumor , BLRM ( Bayesian logistic regression model )</keyword>
</DOC>